← SGLT2 inhibitors × body weight & composition

TrialThe Journal of clinical endocrinology and metabolism2012

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.

Jan Bolinder et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 182 people · 2012

Randomised comparison

Probably lowered body weight & composition

−2.08kg−2.84 to −1.31

As reported

difference −2.08 kg, 95% CI −2.84 to −1.31

Randomised comparison

Probably lowered body weight & composition

−26.2percentage points−36.7 to −15.5

As reported

difference −26.2 %, 95% CI −36.7 to −15.5

Two numbers in the abstract

the abstract, start to end

… with dapagliflozin were as follows: TBW, -2.08 kg [95% confidence interval (CI)=-2.84 to -1.31; P<0.0001]; waist circumference, -1.52 cm (95% CI=-2.74 to -0.31; P=0.0143); FM, -1.48 kg (95% CI=-2.22 to -0.74; P=0.0001); proportion of patients achieving weight reduction of at least 5%, +26.2% (95% CI=15.5 to 36.7; …

← favours treatmentfavours comparator →
could be chance
Body weight & composition
−2.08−2.84 to −1.31
Body weight & composition
−26.2−36.7 to −15.5
SGLT2 inhibitorsBody weight & composition

SGLT2 inhibitors × body weight & compositionhelps?settled

unlikelylikely
0.980.98 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

401 papers cite itlatest 60 shown

2012
…
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

6 trials

Full record →Abstract, authors, funding and every citing paper · PMID 22238392